(PHILADELPHIA) – In 2002, Thomas and Carol
Hallinan, of Northeast Philadelphia, lost their son, Peter, 31,
Oligodendroglioma – a type of brain
affects 190,000 people in the U.S. each year, and is the second
most common cause of cancer death in young people ages 15-34. To
honor their son’s memory, The Hallinans have partnered
with the University of Pennsylvania Health
System and Penn’s Department
of Neurosurgery to
build support for the advancement of clinical research for patients
who suffer from brain tumors. “For Pete’s Sake” – an
evening of dinner, dancing, and a silent auction – is a sold-out
event with an expected attendance of 250 people. Proceeds
will support brain tumor research at Penn.
PENN Medicine is a $2.9 billion enterprise
dedicated to the related missions of medical education, biomedical
research, and high-quality patient care. PENN Medicine consists
of the University of Pennsylvania School of Medicine (founded in
1765 as the nation's first medical school) and the University of
Pennsylvania Health System.
Penn's School of Medicine is ranked #2 in the nation for receipt
of NIH research funds; and ranked #3 in the nation in U.S. News
& World Report's most recent ranking of top research-oriented
medical schools. Supporting 1,400 fulltime faculty and 700 students,
the School of Medicine is recognized worldwide for its superior
education and training of the next generation of physician-scientists
and leaders of academic medicine.
The University of Pennsylvania Health System includes three hospitals,
all of which have received numerous national patient-care honors [Hospital
of the University of Pennsylvania; Pennsylvania Hospital, the nation's
first hospital; and Penn Presbyterian Medical Center]; a faculty practice
plan; a primary-care provider network; two multispecialty satellite
facilities; and home care and hospice.